Halozyme Therapeutics Inc. (NASDAQ: HALO) on Tuesday, plunged -1.05% from the previous trading day, before settling in for the closing price of $57.24. Within the past 52 weeks, HALO’s price has moved between $32.83 and $65.53.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 41.16% over the past five years. The company achieved an average annual earnings per share of 43.64%. With a float of $125.30 million, this company’s outstanding shares have now reached $126.77 million.
Let’s look at the performance matrix of the company that is accounted for 373 employees.
Halozyme Therapeutics Inc. (HALO) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Halozyme Therapeutics Inc. is 1.09%, while institutional ownership is 97.28%. The most recent insider transaction that took place on Sep 24 ’24, was worth 582,100. In this transaction PRESIDENT AND CEO of this company sold 10,000 shares at a rate of $58.21, taking the stock ownership to the 676,744 shares. Before that another transaction happened on Sep 25 ’24, when Company’s PRESIDENT AND CEO sold 10,000 for $56.34, making the entire transaction worth $563,370. This insider now owns 676,744 shares in total.
Halozyme Therapeutics Inc. (HALO) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 43.64% per share during the next fiscal year.
Halozyme Therapeutics Inc. (NASDAQ: HALO) Trading Performance Indicators
Halozyme Therapeutics Inc. (HALO) is currently performing well based on its current performance indicators. A quick ratio of 6.21 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.22. Likewise, its price to free cash flow for the trailing twelve months is 17.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.58, a number that is poised to hit 0.99 in the next quarter and is forecasted to reach 4.75 in one year’s time.
Technical Analysis of Halozyme Therapeutics Inc. (HALO)
Halozyme Therapeutics Inc. (NASDAQ: HALO) saw its 5-day average volume 1.27 million, a positive change from its year-to-date volume of 1.27 million. As of the previous 9 days, the stock’s Stochastic %D was 19.31%. Additionally, its Average True Range was 1.70.
During the past 100 days, Halozyme Therapeutics Inc.’s (HALO) raw stochastic average was set at 63.33%, which indicates a significant increase from 14.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.48% in the past 14 days, which was lower than the 33.97% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $58.59, while its 200-day Moving Average is $45.95. Nevertheless, the first resistance level for the watch stands at $57.26 in the near term. At $57.87, the stock is likely to face the second major resistance level. The third major resistance level sits at $58.56. If the price goes on to break the first support level at $55.96, it is likely to go to the next support level at $55.27. Assuming the price breaks the second support level, the third support level stands at $54.66.
Halozyme Therapeutics Inc. (NASDAQ: HALO) Key Stats
Market capitalization of the company is 7.18 billion based on 127,274K outstanding shares. Right now, sales total 829,250 K and income totals 281,590 K. The company made 231,350 K in profit during its latest quarter, and 93,250 K in sales during its previous quarter.
